Literature DB >> 19917310

Alteration of Methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120.

Amanda J Roberts1, Ricky Maung, Natalia E Sejbuk, Christopher Ake, Marcus Kaul.   

Abstract

The use of drugs for recreational purposes, in particular Methamphetamine, is associated with an increased risk of infection with human immunodeficiency virus (HIV)-1. HIV-1 infection in turn can lead to HIV-associated neurological disorders (HAND) that range from mild cognitive and motor impairment to HIV-associated dementia (HAD). Interestingly, post mortem brain specimens from HAD patients and transgenic (tg) mice expressing the viral envelope protein gp120 in the central nervous system display similar neuropathological signs. In HIV patients, the use of Methamphetamine appears to aggravate neurocognitive alterations. In the present study, we injected HIV/gp120tg mice and non-transgenic littermate control animals with Methamphetamine dissolved in Saline or Saline vehicle and assessed locomotion and stereotyped behaviour. We found that HIVgp120-transgenic mice differ significantly from non-transgenic controls in certain domains of their behavioural response to Methamphetamine. Thus this experimental model system may be useful to further study the mechanistic interaction of both the viral envelope protein and the psychostimulant drug in behavioural alterations and neurodegenerative disease. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917310      PMCID: PMC3432271          DOI: 10.1016/j.jneumeth.2009.11.007

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  15 in total

1.  Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120.

Authors:  R D'hooge; F Franck; L Mucke; P P De Deyn
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

2.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

Review 3.  Stereotyped behaviour in animals induced by stimulant drugs or by a restricted cage environment: relation to disintegrated behaviour, brain dopamine and psychiatric disease.

Authors:  A Randrup; G Sørensen; M Kobayashi
Journal:  Yakubutsu Seishin Kodo       Date:  1988-06

Review 4.  Pathways to neuronal injury and apoptosis in HIV-associated dementia.

Authors:  M Kaul; G A Garden; S A Lipton
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

5.  Mice lacking 5-HT receptors show specific impairments in contextual learning.

Authors:  Amanda J Roberts; Thomas Krucker; Coree L Levy; Kristen A Slanina; J Gregor Sutcliffe; Peter B Hedlund
Journal:  Eur J Neurosci       Date:  2004-04       Impact factor: 3.386

Review 6.  Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation.

Authors:  J L Cadet; I N Krasnova
Journal:  Neurotox Res       Date:  2007-10       Impact factor: 3.911

7.  Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons.

Authors:  Julie D Rippeth; Robert K Heaton; Catherine L Carey; Thomas D Marcotte; David J Moore; Raul Gonzalez; Tanya Wolfson; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2004-01       Impact factor: 2.892

8.  Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic.

Authors:  Antonio Urbina; Kristina Jones
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

9.  Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice.

Authors:  S M Toggas; E Masliah; E M Rockenstein; G F Rall; C R Abraham; L Mucke
Journal:  Nature       Date:  1994-01-13       Impact factor: 49.962

10.  Methamphetamine inhibits antigen processing, presentation, and phagocytosis.

Authors:  Zsolt Tallóczy; Jose Martinez; Danielle Joset; Yonaton Ray; Attila Gácser; Sima Toussi; Noboru Mizushima; Joshua D Nosanchuk; Josh Nosanchuk; Harris Goldstein; John Loike; David Sulzer; Laura Santambrogio
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

View more
  21 in total

Review 1.  Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Authors:  Ricky Maung; Kathryn E Medders; Natalia E Sejbuk; Maya K Desai; Rossella Russo; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

Review 2.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 3.  Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models.

Authors:  Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

Review 4.  Role of microglia in methamphetamine-induced neurotoxicity.

Authors:  Enquan Xu; Jianuo Liu; Han Liu; Xiaobei Wang; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-06-15

5.  D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity.

Authors:  Michael Y Aksenov; M V Aksenova; C F Mactutus; Rosemarie M Booze
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-03       Impact factor: 4.147

Review 6.  The HIV-1 transgenic rat model of neuroHIV.

Authors:  Michael Vigorito; Kaitlyn P Connaghan; Sulie L Chang
Journal:  Brain Behav Immun       Date:  2015-02-27       Impact factor: 7.217

7.  Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice.

Authors:  James P Kesby; David T Hubbard; Athina Markou; Svetlana Semenova
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

8.  Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice.

Authors:  Brook L Henry; Mark A Geyer; Mahalah Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Brain Res       Date:  2012-08-31       Impact factor: 3.332

9.  CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120.

Authors:  Ricky Maung; Melanie M Hoefer; Ana B Sanchez; Natalia E Sejbuk; Kathryn E Medders; Maya K Desai; Irene C Catalan; Cari C Dowling; Cyrus M de Rozieres; Gwenn A Garden; Rossella Russo; Amanda J Roberts; Roy Williams; Marcus Kaul
Journal:  J Immunol       Date:  2014-07-16       Impact factor: 5.422

Review 10.  Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior.

Authors:  Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.